Skip to main content

Advertisement

Table 4 Univariate and multivariate analyses of the relationship of CD44+/CD24-/low tumor cells to overall survival

From: CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma

Variable Univariate analysis Multivariate analysis
HR 95% CI p-value HR 95% CI p-value
CD44+/CD24-/low tumor cells
High 2.193 1.383-3.477 0.001 2.237 1.345-3.720 0.002
Low 1.000    1.000   
ER status
Positive 0.757 0.488-1.175 0.215 1.164 0.585-2.314 0.665
Negative 1.000    1.000   
PR status
Positive 0.702 0.457–1.078 0.106 0.968 0.496–1.888 0.924
Negative 1.000    1.000   
Her2 status
Positive 0.932 0.605–1.435 0.748 1.583 0.782–3.201 0.201
Negative 1.000    1.000   
Basal-like feature*
Present 0.608 0.389-0.949 0.029 0.342 0.131-0.891 0.028
Absent 1.000    1.000   
TNM stage
Stage III/IV 1.614 1.055–2.470 0.027 1.652 1.014–2.690 0.044
Stage I/II 1.000    1.000   
Lymph node involvement
Absent 0.891 0.528-1.504 0.666 0.674 0.343-1.323 0.251
Present 1.000    1.000   
Age (years)
≥ 50 1.110 0.735–1.676 0.621 1.384 0.847–2.260 0.194
< 50 1.000    1.000   
  1. Abbreviations: HR, hazard ratio estimated from Cox proportional hazard regression model; CI, confidence interval of the estimated HR. ER, estrogen receptor; PR, progesterone receptor; Her2, human epidermal growth factor receptor 2.
  2. * Immunohistochemically negative for both SR and Her2.